With box warnings

Without box warnings

Branded

Generic

3 results

imbruvica
(Ibrutinib)
Pharmacyclics LLC
Usage: IMBRUVICA is indicated for adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), CLL/SLL with 17p deletion, Waldenström’s macroglobulinemia, and for treating chronic graft-versus-host disease in patients aged 1 year and older after failure of prior systemic therapy.
jakafi
(ruxolitinib)
Incyte Corporation
Usage: Jakafi is indicated for treating intermediate or high-risk myelofibrosis, polycythemia vera in adults intolerant to hydroxyurea, and steroid-refractory acute and chronic graft-versus-host disease in patients aged 12 and older who have not responded to prior systemic therapies.
niktimvo
(axatilimab-csfr)
Incyte Corporation
Usage: NIKTIMVO is indicated for the treatment of chronic graft-versus-host disease (cGVHD) in adults and pediatric patients weighing at least 40 kg, following the failure of at least two prior lines of systemic therapy.

Medications for Chronic Graftversushost Disease

imbruvica